Developer docs
API playgroundTry for free, no card

Search company profiles

Evolutia Bio

Full company profile

uuid003oxdt

Namestring
Evolutia Bio
Legal namestring
Evolutia Bio
Websiteurl
willowbio.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Evolutia Bio is a contract biomanufacturing firm that develops custom enzymes, engineered microbial strains, and fermentation/downstream processes for ingredient and industrial partners. The company's underlying platform combines AI-guided enzyme diversity generation and recombination, genome-wide strain improvement, high-throughput screening, and a proprietary BioOxi™ oxidation platform, with the explicit goal of moving novel biology from laboratory demonstration to commercially viable production. Formerly operating as Willow Biosciences / Epimeron Inc, the company was acquired by Mycofeast in 2025 and now positions itself as the development-stage arm of an integrated Evolutia–Mycofeast offering that connects AI-enabled enzyme and strain engineering with Mycofeast's bench-to-pilot-to-plant translation and industrial fermentation infrastructure.

Evolutia Bio generates revenue primarily through B2B contract development services, charging milestone-based project fees that span feasibility evaluation, optimization, and scale-up phases, with the potential for ongoing royalties or shared manufacturing economics once commercial deployment is reached. Its go-to-market is consultative enterprise field sales: prospective partners engage through the company website, specify target molecules, sector, and development stage, and Evolutia evaluates whether biology offers a viable manufacturing route. Served verticals include Food & Ingredients (the primary segment), Agriculture, Pharma & Fine Chemicals, and Industrial Biomanufacturing, with the website contact form also listing Consumer Care and Flavour & Fragrance as adjacent sectors. Pricing is not publicly disclosed and engagements are scoped individually.

The company is privately held and headquartered in San Carlos, California, operating with a small team (11–50 employees) led by Managing Directors Chris Davis and Jason Lewis, alongside Senior Director of Genetic Engineering Vesna Mitchell. No funding rounds, patents, named customers, or revenue figures are disclosed in the available data, and there are no public certifications, awards, or regulatory actions on record.

Short descriptiontext

Evolutia Bio is a private biomanufacturing services provider that develops custom enzymes, engineered microbial strains, and fermentation processes for ingredient and industrial partners, combining AI-guided enzyme design and its BioOxi™ oxidation platform with Mycofeast's industrial fermentation and scale-up infrastructure.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Carlos, United States
HQ citystring
San Carlos
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
custom enzyme design, strain engineering services, bioprocess development, fermentation process development, contract biomanufacturing services
Industry3 codes
PRIMARYAFABAEAM
Biological Formulation, Fermentation & Scale-Up Manufacturing
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Biologicals & Biopesticides (Microbials, Botanicals, Beneficial Insects)
SECONDARYEUAAAIAL
Enzymes & Industrial Biotechnology Inputs (Enzymes, Microbial Strains, Fermentation Aids)
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
SECONDARYHLAAAJAM
Data, Digital Twin & Advanced Analytics for Biomanufacturing (AI/ML, multivariate, historian)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
Product category
Contract Biomanufacturing Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1B2B Contract Development Services
TypeProfessional Services
Description

Evolutia Bio earns revenue by developing custom enzymes, engineered microbial strains, and biomanufacturing processes under contractual agreements with ingredient and industrial partners. Revenue is generated through milestone-based project fees spanning feasibility, optimization, and scale-up phases, with commercial deployment potentially unlocking ongoing royalties or manufacturing fees shared with Mycofeast.

evolutiabio.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1BioOxi™
Description

Oxidation platform for biomanufacturing processes

evolutiabio.com
Core offering1 text field

Evolutia Bio develops custom enzymes, engineered microbial strains, and biomanufacturing processes for ingredient and industrial partners. The company combines AI-guided enzyme engineering, genome-wide strain improvement, high-throughput screening, and the proprietary BioOxi™ oxidation platform with Mycofeast's scale-up and manufacturing infrastructure to deliver a complete path from concept to commercial production.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Evolutia Bio is a biomanufacturing solutions provider that offers a portfolio of integrated services organized around custom enzymes, strain engineering, and process development. The company operates as a unified platform combining AI-guided enzyme engineering with genome-wide strain improvement and high-throughput screening capabilities, including the proprietary BioOxi™ oxidation platform. Formerly Willow Biosciences / Epimeron Inc, acquired by Mycofeast in 2025, Evolutia Bio partners with Mycofeast to provide a complete path from concept to commercial production, serving industries including Food & Ingredients, Agriculture, Pharma & Fine Chemicals, and Industrial Biomanufacturing.

Product and service4 records
1Custom Enzymes
Categorycore service
Description

Design and optimization of enzymes for valuable and difficult chemical transformations using AI-guided diversity generation and recombination workflows, delivered to ingredient and industrial partners.

2Strain Engineering
Categorycore service
Description

Improvement of microbial production hosts for better titer, robustness, and product profile through genome-wide engineering approaches, delivered to ingredient and industrial partners.

3Process Development
Categorycore service
Description

Build practical biomanufacturing development workflows from screening through fermentation, downstream optimization, and scale-up readiness for ingredient and industrial partners.

4BioOxi™ Oxidation Platform
Categoryplatform technology
Description

Proprietary AI-enabled oxidation platform enabling bio-based oxidation reactions for the production of high-value molecules, used in biomanufacturing processes for ingredient and industrial partners.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Mycofeast acquired Evolutia Bio (formerly Willow Biosciences / Epimeron Inc.) in 2025, creating an integrated biomanufacturing entity. Evolutia contributes its AI-guided enzyme engineering, genome-wide strain improvement, and process development capabilities, while Mycofeast provides bench-to-pilot-to-plant translation, industrial fermentation expertise, production infrastructure, and scale-up and commercial deployment capabilities. Together they offer a complete route from concept to commercial production for ingredient and industrial partners.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Conagen develops custom enzymes, engineered strains, and fermentation processes for food, flavor, fragrance, and pharma customers, directly overlapping Evolutia's custom enzymes and strain engineering services.

TypeDirect peer
Description

Amyris operates fermentation-based biomanufacturing for ingredients and specialty chemicals, sharing Evolutia's model of translating engineered strains into commercial ingredient production.

TypeOthers
Description

Twist Bioscience provides synthetic DNA and DNA-based discovery tools used by enzyme engineers and synthetic biology companies, an enabler/ecosystem participant relevant to Evolutia's platform.

TypeBroad incumbent
Description

Ginkgo Bioworks is a broad incumbent in synthetic biology and cell engineering, offering organism design and biomanufacturing services across multiple verticals at greater scale than Evolutia.

TypeBroad incumbent
Description

Biosynth is a broad incumbent supplying specialty biochemicals, peptides, and custom synthesis services, an adjacent peer in the chemicals and ingredients supply chain Evolutia targets.

6Culture Biosciences
TypeEmerging player
Description

Culture Biosciences is a fermentation CDMO offering bioreactor capacity and process development services, overlapping with Evolutia's process development and scale-up readiness work.

TypeEmerging player
Description

Arzeda uses AI and computational protein design to engineer enzymes and pathways for chemicals and ingredients, an emerging peer in AI-guided enzyme design that overlaps with Evolutia's AI workflows.

TypeDirect peer
Description

Codexis is a direct peer: it engineers enzymes and develops bioprocesses for pharmaceutical, food, and industrial customers using protein engineering and fermentation, closely mirroring Evolutia's core offering.

TypeBroad incumbent
Description

DSM-Firmenich (with its enzymes and biomanufacturing operations) is a broad incumbent producing industrial enzymes and fermented ingredients at scale, setting the competitive benchmark for Evolutia in food and industrial biomanufacturing.

TypeEmerging player
Description

Bota Bio is an emerging player applying synthetic biology and fermentation to produce ingredients and specialty chemicals, comparable to Evolutia's industrial biomanufacturing positioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Evolutia Bio

Contract Biomanufacturing Serviceswillowbio.com

Evolutia Bio is a private biomanufacturing services provider that develops custom enzymes, engineered microbial strains, and fermentation processes for ingredient and industrial partners, combining AI-guided enzyme design and its BioOxi™ oxidation platform with Mycofeast's industrial fermentation and scale-up infrastructure.

What Evolutia Bio does

Evolutia Bio is a contract biomanufacturing firm that develops custom enzymes, engineered microbial strains, and fermentation/downstream processes for ingredient and industrial partners. The company's underlying platform combines AI-guided enzyme diversity generation and recombination, genome-wide strain improvement, high-throughput screening, and a proprietary BioOxi™ oxidation platform, with the explicit goal of moving novel biology from laboratory demonstration to commercially viable production. Formerly operating as Willow Biosciences / Epimeron Inc, the company was acquired by Mycofeast in 2025 and now positions itself as the development-stage arm of an integrated Evolutia–Mycofeast offering that connects AI-enabled enzyme and strain engineering with Mycofeast's bench-to-pilot-to-plant translation and industrial fermentation infrastructure.

Evolutia Bio generates revenue primarily through B2B contract development services, charging milestone-based project fees that span feasibility evaluation, optimization, and scale-up phases, with the potential for ongoing royalties or shared manufacturing economics once commercial deployment is reached. Its go-to-market is consultative enterprise field sales: prospective partners engage through the company website, specify target molecules, sector, and development stage, and Evolutia evaluates whether biology offers a viable manufacturing route. Served verticals include Food & Ingredients (the primary segment), Agriculture, Pharma & Fine Chemicals, and Industrial Biomanufacturing, with the website contact form also listing Consumer Care and Flavour & Fragrance as adjacent sectors. Pricing is not publicly disclosed and engagements are scoped individually.

The company is privately held and headquartered in San Carlos, California, operating with a small team (11–50 employees) led by Managing Directors Chris Davis and Jason Lewis, alongside Senior Director of Genetic Engineering Vesna Mitchell. No funding rounds, patents, named customers, or revenue figures are disclosed in the available data, and there are no public certifications, awards, or regulatory actions on record.

Evolutia Bio firmographics

Firmographics
Name
Evolutia Bio
Legal name
Evolutia Bio
Website
https://willowbio.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Evolutia Bio is a private biomanufacturing services provider that develops custom enzymes, engineered microbial strains, and fermentation processes for ingredient and industrial partners, combining AI-guided enzyme design and its BioOxi™ oxidation platform with Mycofeast's industrial fermentation and scale-up infrastructure.
Ownership category
akta.pro rank

Evolutia Bio industry classification

Industry
Product category
Contract Biomanufacturing Services
akta.pro industry
PRIMARYAFABAEAM
Biological Formulation, Fermentation & Scale-Up Manufacturing
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Biologicals & Biopesticides (Microbials, Botanicals, Beneficial Insects)
SECONDARYEUAAAIAL
Enzymes & Industrial Biotechnology Inputs (Enzymes, Microbial Strains, Fermentation Aids)
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
SECONDARYHLAAAJAM
Data, Digital Twin & Advanced Analytics for Biomanufacturing (AI/ML, multivariate, historian)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)

Keywords

  • Custom enzyme design
  • Strain engineering services
  • Bioprocess development
  • Fermentation process development
  • Contract biomanufacturing services

Where Evolutia Bio is headquartered

Location

Headquarters

HQ city
San Carlos
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Evolutia Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. B2B Contract Development Services: Evolutia Bio earns revenue by developing custom enzymes, engineered microbial strains, and biomanufacturing processes under contractual agreements with ingredient and industrial partners. Revenue is generated through milestone-based project fees spanning feasibility, optimization, and scale-up phases, with commercial deployment potentially unlocking ongoing royalties or manufacturing fees shared with Mycofeast.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Evolutia Bio product offering

Product offering

Core offering

Evolutia Bio develops custom enzymes, engineered microbial strains, and biomanufacturing processes for ingredient and industrial partners. The company combines AI-guided enzyme engineering, genome-wide strain improvement, high-throughput screening, and the proprietary BioOxi™ oxidation platform with Mycofeast's scale-up and manufacturing infrastructure to deliver a complete path from concept to commercial production.

Product overview

Evolutia Bio is a biomanufacturing solutions provider that offers a portfolio of integrated services organized around custom enzymes, strain engineering, and process development. The company operates as a unified platform combining AI-guided enzyme engineering with genome-wide strain improvement and high-throughput screening capabilities, including the proprietary BioOxi™ oxidation platform. Formerly Willow Biosciences / Epimeron Inc, acquired by Mycofeast in 2025, Evolutia Bio partners with Mycofeast to provide a complete path from concept to commercial production, serving industries including Food & Ingredients, Agriculture, Pharma & Fine Chemicals, and Industrial Biomanufacturing.

Differentiator

Problem solved

Functional benefit

Brands

  • BioOxi™: Oxidation platform for biomanufacturing processes

Products and services

  • Custom Enzymes Design and optimization of enzymes for valuable and difficult chemical transformations using AI-guided diversity generation and recombination workflows, delivered to ingredient and industrial partners.
  • Strain Engineering Improvement of microbial production hosts for better titer, robustness, and product profile through genome-wide engineering approaches, delivered to ingredient and industrial partners.
  • Process Development Build practical biomanufacturing development workflows from screening through fermentation, downstream optimization, and scale-up readiness for ingredient and industrial partners.
  • BioOxi™ Oxidation Platform Proprietary AI-enabled oxidation platform enabling bio-based oxidation reactions for the production of high-value molecules, used in biomanufacturing processes for ingredient and industrial partners.

Companies that use Evolutia Bio

Customer profile

Segments4 records

Ideal customer profiles4 records

Evolutia Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Evolutia Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • MycofeastcoreStrategic or Co-development Partner · 1 January 2025Mycofeast acquired Evolutia Bio (formerly Willow Biosciences / Epimeron Inc.) in 2025, creating an integrated biomanufacturing entity. Evolutia contributes its AI-guided enzyme engineering, genome-wide strain improvement, and process development capabilities, while Mycofeast provides bench-to-pilot-to-plant translation, industrial fermentation expertise, production infrastructure, and scale-up and commercial deployment capabilities. Together they offer a complete route from concept to commercial production for ingredient and industrial partners.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Evolutia Bio competitors and assessment

Company assessment

Direct peers

  • Conagen: Conagen develops custom enzymes, engineered strains, and fermentation processes for food, flavor, fragrance, and pharma customers, directly overlapping Evolutia's custom enzymes and strain engineering services.
  • Amyris: Amyris operates fermentation-based biomanufacturing for ingredients and specialty chemicals, sharing Evolutia's model of translating engineered strains into commercial ingredient production.
  • Codexis: Codexis is a direct peer: it engineers enzymes and develops bioprocesses for pharmaceutical, food, and industrial customers using protein engineering and fermentation, closely mirroring Evolutia's core offering.

Others

  • Twist Bioscience: Twist Bioscience provides synthetic DNA and DNA-based discovery tools used by enzyme engineers and synthetic biology companies, an enabler/ecosystem participant relevant to Evolutia's platform.

Broad incumbents

  • Ginkgo Bioworks: Ginkgo Bioworks is a broad incumbent in synthetic biology and cell engineering, offering organism design and biomanufacturing services across multiple verticals at greater scale than Evolutia.
  • Biosynth: Biosynth is a broad incumbent supplying specialty biochemicals, peptides, and custom synthesis services, an adjacent peer in the chemicals and ingredients supply chain Evolutia targets.
  • Crinetics Pharmaceuticals / Novozymes / DSM-Firmenich (enzymes division): DSM-Firmenich (with its enzymes and biomanufacturing operations) is a broad incumbent producing industrial enzymes and fermented ingredients at scale, setting the competitive benchmark for Evolutia in food and industrial biomanufacturing.

Emerging players

  • Culture Biosciences: Culture Biosciences is a fermentation CDMO offering bioreactor capacity and process development services, overlapping with Evolutia's process development and scale-up readiness work.
  • Arzeda: Arzeda uses AI and computational protein design to engineer enzymes and pathways for chemicals and ingredients, an emerging peer in AI-guided enzyme design that overlaps with Evolutia's AI workflows.
  • Bota Bio: Bota Bio is an emerging player applying synthetic biology and fermentation to produce ingredients and specialty chemicals, comparable to Evolutia's industrial biomanufacturing positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Evolutia Bio social profiles

Digital presence

Evolutia Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Evolutia Bio leadership team

Management profile

Number of profiles

Profiles3 records

Evolutia Bio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Evolutia Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evolutia Bio

What does Evolutia Bio do?

Evolutia Bio develops custom enzymes, engineered microbial strains, and biomanufacturing processes for ingredient and industrial partners. The company combines AI-guided enzyme engineering, genome-wide strain improvement, high-throughput screening, and the proprietary BioOxi™ oxidation platform with Mycofeast's scale-up and manufacturing infrastructure to deliver a complete path from concept to commercial production.

Is Evolutia Bio a public or private company?

Evolutia Bio is a private company. It is classified as corporate owned and is currently operating.

When was Evolutia Bio founded?

Evolutia Bio was founded in 2019. It employs 11 to 50 people.

Where is Evolutia Bio based?

Evolutia Bio is headquartered in San Carlos, United States, in the North America region.

How does Evolutia Bio make money?

One revenue line is on record: B2B Contract Development Services.

Who are Evolutia Bio's main competitors?

Direct peers on record are Conagen, Amyris and Codexis. Twist Bioscience is listed as an others. Broad incumbents are Ginkgo Bioworks, Biosynth and Crinetics Pharmaceuticals / Novozymes / DSM-Firmenich (enzymes division). Emerging players are Culture Biosciences, Arzeda and Bota Bio.

Does Evolutia Bio have an API?

No public API is recorded for Evolutia Bio.

What industry is Evolutia Bio in?

Evolutia Bio's product category is Contract Biomanufacturing Services. Its primary akta.pro industry code is AFABAEAM, Biological Formulation, Fermentation & Scale-Up Manufacturing, with a secondary code of EUAAAIAL, Enzymes & Industrial Biotechnology Inputs (Enzymes, Microbial Strains, Fermentation Aids).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TipranksWillow Biosciences Inc. Receives Conditional TSXV Listing ApprovalWillow Biosciences Inc. received conditional acceptance to list its common shares on the TSX Venture Exchange under the Sandbox Program, with trading expected to commence on June 24, 2025. The company must complete a $30 million private placement and invest in qualifying projects within 12 months to maintain its listing.NewswireWILLOW BIOSCIENCES INC. ANNOUNCES CONDITIONAL ACCEPTANCE OF TSX VENTURE EXCHANGE TO LIST PURSUANT TO THE TSXV SANDBOXWillow Biosciences received conditional acceptance to list on the TSXV Sandbox after a $30 million private placement and share consolidation. The company will trade as Atlas Energy Corp. under symbol ATLE on June 24, 2025, with shareholders approving the consolidation. It must meet exit conditions within 12 months, otherwise listing may transfer to NEX.NewswireWILLOW BIOSCIENCES INC. ANNOUNCES COMPLETION OF SALE OF OPERATING SUBSIDIARY AND MANAGEMENT CHANGESWillow Biosciences completed the sale of its operating subsidiary Epimeron USA to a Mycofeast subsidiary for $2.76 million in cash, with $275,975 held in escrow. The company will use proceeds for debt reduction and retains the remainder pending review of futures cash requirements. Dr. Chris Savile and Dr. Trish Choudhary resigned to join the purchaser, and Travis Doupe became interim CEO.The Globe and MailBiotech on An Upswing Following Licensing and Royalty AgreementWillow Biosciences signed a commercial license and royalty agreement with Kalsec to manufacture a natural ingredient for savory food applications. The deal includes milestone payments for pilot and industrial batches, plus tiered royalties on net worldwide sales. Willow expects the R&D phase to complete in 2024, with regulatory and scale-up work continuing into 2025.Business & FinancialCannabisnewsbreaks Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) To Receive Advisory Services, Funding For Rare Cannabinoid Development PlatformWillow Biosciences' subsidiary Willow Analytics will receive advisory services and conditional funding from the National Research Council of Canada's Industrial Research Assistance Program. The funding supports research and development to advance production of its varin cannabinoids using a proprietary biosynthetic platform. The company aims to progress from lab-scale work to pre-commercialization scale-up.NewswireWILLOW ANNOUNCES BROKERED PRIVATE PLACEMENT OFFERING TO RAISE UP TO $3.0 MILLIONWillow Biosciences Inc. announced a brokered private placement offering to raise up to C$3.0 million through the sale of 30,000,000 units at C$0.10 per unit. The company intends to use the proceeds to support enzyme engineering, fund a strategic partnership with Laurus Labs for active pharmaceutical ingredients, and cover working capital requirements. Independent Trading Group will act as the lead agent for this "best efforts" offering, which is open to investors in Canada and the United States.BenzingaCBG Producer Willow Biosciences Announces Record 43% Revenue Increase And Strategic Moves Ahead - Willow Biosciences (OTC:CANSF)Willow Biosciences reported record revenue of $1.2 million, a 43% increase from the prior year, and completed consolidation of its laboratory operations in Sunnyvale, California. The company also announced four new partnerships and expects over 100% R&D revenue growth in 2024.ProactiveinvestorsWillow Biosciences unveils second strategic investment from KalsecWillow Biosciences announced that Kalsec has completed a second strategic investment of US$100,000 following the achievement of an operational milestone on February 23. Willow issued 1,153,131 units to Kalsec at C$0.12 per unit to fund the commercialization and development of its precision fermentation product pipeline. The proceeds will support working capital and general corporate purposes for the biotech firm.PR NewswireWILLOW BIOSCIENCES ANNOUNCES SECOND STRATEGIC INVESTMENT FROM KALSECWillow Biosciences Inc. announced a second strategic investment of US$100,000 from Kalsec Inc., triggered by Willow achieving an operational milestone for developing a specific strain on February 23, 2024. The company issued 1,153,131 units at C$0.12 per unit to raise capital for the commercialization and development of its natural food ingredients pipeline. This transaction follows an initial commitment made by Kalsec in February 2024 upon signing a broader partnership agreement.BenzingaAurora Cannabis And Willow Biosciences Complete Patent Settlement - Aurora Cannabis (NASDAQ:ACB), Willow Biosciences (OTC:CANSF)Aurora Cannabis and Willow Biosciences completed a confidential settlement resolving patent litigation. Aurora had sued in July 2021 over Willow's biosynthetic process for cannabinoids, alleging infringement of co-owned patents. Aurora's CEO said the settlement ensures its Canadian cannabis-related patent rights are respected.